A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
March 27th, 2017
Herein we report a tailored HPLC purification protocol that yields high-purity amyloid beta 42 (Aβ42) and amyloid beta 40 (Aβ40) peptides, capable of oligomer formation. Amyloid beta is a highly aggregation prone, hydrophobic peptide implicated in Alzheimer's disease. The amyloidogenic nature of the peptide makes its purification a challenge.
The overall goal of this procedure is to use HPLC purification to produce high purity amyloid beta 42, and amyloid beta 40 peptides that are capable of forming oligomers.The biochemical properties of the amyloid beta peptide can often make its purification difficult.Therefore, the obtainment of high purity peptide that is capable of oligomer formation can be challenging.This procedure helps to alleviate that challenge.For this HPLC protocol, have prepared stocks of buffers A and B ready as well as the buffer for sample dissolution.To set up the HPLC, first fit the bottles of buffer A and B to the inlets of the pump.Use polymer tubing and one piece fittings and don't mix up the valves.Connect the polymer tubing from the pump outlet to the inlet of the preparative column.Make the one piece fitting finger tight, and make certain the column is in the correct orientation.Now secure another polymer tube from the outlet of the column to the dual wavelength detector.Use finger tight one piece fittings, then, in the HPLC setup software, set the wavelength detector to measure peaks at 214 and 280 nanometers.Next, connect the output valve of the wave length detector to the outlet valve of the HPLC detector using polymer tubing and a one piece fitting made finger tight.This will serve as the sample collection tubing.Now program the HPLC software to run the purification method.From the Set up Instrument Method option, enter the purification method by changing the solvent timetable parameter.Lastly, turn on the HPLC pump from the HPLC software.Now the pump will start supplying the starting ratio of buffer A and buffer B through the preparative column in the HPLC instrument.It is vital to now let the system equilibrate for 30 minutes before proceeding with samples.To begin, dissolve three milligrams of crude A
View the full transcript and gain access to thousands of scientific videos
Overview
This study presents a tailored HPLC purification protocol for high-purity amyloid beta 42 (Aβ42) and amyloid beta 40 (Aβ40) peptides. These peptides are known for their aggregation propensity and are implicated in Alzheimer's disease, making their purification a significant challenge.
Key Study Components
Area of Science
- Neuroscience
- Biochemistry
- Alzheimer's Disease Research
Background
- Amyloid beta peptides are hydrophobic and prone to aggregation.
- Purification of these peptides is critical for studying their role in Alzheimer's disease.
- High-purity peptides are necessary for oligomer formation studies.
- Existing purification methods may not yield sufficient purity.
Purpose of Study
- To develop a reliable HPLC purification protocol.
- To obtain high-purity Aβ42 and Aβ40 peptides.
- To facilitate further research on amyloid beta oligomers.
Methods Used
- High-Performance Liquid Chromatography (HPLC)
- Tailored purification protocols
- Characterization of peptide purity
- Assessment of oligomer formation capability
Main Results
- Successful purification of Aβ42 and Aβ40 peptides.
- High purity levels achieved through the new protocol.
- Peptides demonstrated the ability to form oligomers.
- Protocol effectiveness compared to existing methods.
Conclusions
- The tailored HPLC protocol is effective for peptide purification.
- High-purity amyloid beta peptides are essential for Alzheimer's research.
- This study provides a foundation for future investigations into amyloid beta oligomers.
Frequently Asked Questions
Executive Industry Relevance
Obtaining high-purity amyloid beta peptides is a critical bottleneck in Alzheimer's disease target validation and oligomerization studies. This HPLC purification protocol enables reproducible production of Aβ42 and Aβ40 peptides with >95% purity, supporting reliable oligomer formation assays. The method provides a scalable, standardized approach for de-risking target engagement and mechanistic studies in neurodegenerative disease drug discovery.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of amyloid beta oligomerization mechanisms using high-purity peptides.
- Operational Value: Delivers reproducible peptide material for consistent target validation assays.
- Predictive Value: Supports structure-function correlation studies essential for target confidence in Alzheimer's programs.
Screening & Assay Development
- Assay Readiness: Produces purified peptides suitable for oligomerization and binding assays.
- Reproducibility: Ensures batch-to-batch consistency for high-throughput screening campaigns.
- Scalability: Adaptable to analytical and semi-preparative scales depending on peptide quantity needs.
Translational & Preclinical Research
- Disease Relevance: Generates peptides that recapitulate key pathological species in Alzheimer's models.
- Translational Continuity: Bridges discovery-stage peptide production with preclinical oligomer toxicity studies.
- Mechanistic De-risking: Reduces variability in oligomer formation readouts, improving predictive confidence.
Pipeline & Workflow Integration
The protocol fits within the discovery-to-preclinical continuum by supplying validated peptide reagents for target engagement, oligomerization, and toxicity assays.
- Discovery Biology: Supports hypothesis testing on amyloid beta aggregation pathways using pure peptide standards.
- Assay Development: Enables preparation of consistent reagents for oligomer formation and antibody binding assays.
- Analytics: Provides quantifiable, high-purity inputs for HPLC, mass spec, and biophysical characterization.
- Translational Research: Connects peptide purification to downstream oligomerization and cellular toxicity models.
- Enterprise Reuse: Establishes a reusable purification platform for multiple amyloid beta isoforms across projects.
Operational & Enterprise Impact
- Scientific Value: High-purity peptides enable reliable oligomerization studies and target mechanism elucidation.
- Operational Value: Standardized HPLC method ensures reproducibility and reduces purification failure rates.
- Strategic Value: Improves go/no-go decisions by reducing biological noise in oligomerization assays.
- Portfolio Impact: Supports risk-adjusted prioritization of Alzheimer's targets through consistent peptide quality.
Implementation Considerations
- Requires expertise in HPLC method development and peptide handling.
- Needs access to preparative HPLC systems with PLRP-S columns and dual-wavelength detection.
- Demands standardized buffer preparation and sample dissolution protocols.
- Requires adaptation considerations for different peptide quantities and purity thresholds.
- Limited by the solubility and aggregation propensity of amyloid beta peptides under purification conditions.
